Is a major medical breakthrough on the horizon?
A new drug could be a game-changer in Alzheimer’s research following the results of an incredible trial.
Patients given low-dose diranersen injections showed 54% less decline in a test of memory and thinking over nearly two years, suggesting the experimental treatment could slow the deadly disease more effectively than any therapy developed to date, according to the Telegraph.
It is also the first drug to show a decrease in tau, a protein that forms harmful tangles linked to brain cell death.
Diranersen injections use gene-silencing technology to fight Alzheimer’s disease at its source, by blocking RNA messages that signal brain cells to produce tau.
Biogen announced exciting results on Tuesday, November 17, following the Clinical Trials on Alzheimer’s Disease 2026 conference.
“The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit, but also an increasing magnitude of effect after two years,” said Priya Singhal, executive vice president and head of development at Biogen.
“These results reinforce the growing body of evidence supporting Tau as a therapeutic target and highlight the potential for diranersen to have a significant impact on disease progression in people living with early Alzheimer’s disease,” she continued.
What do scientists say?
Professor Reisa Sperling, co-author of the study and professor of neurology at Harvard Medical School, who presented the results of the brain analysis, spoke to the Telegraph, calling the results “exciting.”
“These data suggest that we are not only slowing tau accumulation, but we are reducing aggregated tau protein compared to baseline,” she said.
“We have reversed Alzheimer’s pathology. We have eliminated Tau tangles. That’s a remarkable statement,” Professor Jeffrey Cummings, also a co-author of the study, said at the Alzheimer’s Disease Clinical Trials Conference in Boston, according to the Telegraph.
Lawren VandeVrede, principal investigator of the Phase 2 CELIA study at the University of California, San Francisco, called the results “very encouraging results, especially given the progressive nature of Alzheimer’s disease,” according to Biogen.
“The increasing separation observed between 18 months and two years is remarkable and clinically significant. For patients and families, slowing clinical decline means more time in the early stages, preserving independence, and staying connected to the people and experiences that matter most,” he continued.
What is the continuation of this treatment?
It appears scientists won’t slow the momentum on this potentially life-changing new drug.
British patients are eager to take part in the upcoming diranersen trial, with recruitment in the UK expected to begin in the spring, according to the Telegraph.
Despite the overwhelming positivity, experts noted that a larger phase three trial was needed to confirm the exciting results, although researchers said the treatment in the most recent trial was well tolerated overall.
However, some side effects occurred, including pain associated with lumbar punctures, as well as headache and confusion, which were more common at higher doses.
The new drug has the potential to have a huge impact, as more than seven million Americans live with Alzheimer’s disease, according to the Alzheimer’s Association.
This impressive number is expected to reach almost 13 million by 2050.
Gn bussni
